Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A real world study assessing Secukinumab in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA)

Next Previous
Trial Profile

A real world study assessing Secukinumab in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis; Axial spondyloarthritis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AQUILA

Most Recent Events

  • 15 Jun 2024 Results assessing the effectiveness of SEC on disease activity and QoL in PsA patients depending on pretreatment with biologicals/biosimilars presented at the 25th Annual Congress of the European League Against Rheumatism
  • 15 Nov 2023 Results (n=1257) assessing differential effects of DMARDs on psoriasis area and severity index and patient global assessment in subgroups of patients with active psoriatic arthritis treated over 52-weeks with secukinumab using a multistage clustering approach presented at the ACR Convergence 2023
  • 15 Nov 2023 Results (n=1041) assessing the prediction of low disease activity in patients with psoriatic arthritis presented at the ACR Convergence 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top